InflaRx Plans Two Phase II Izicopan AAV Trials in 2027
InflaRx plans to initiate two Phase II trials of izicopan in ANCA-associated vasculitis in 2027 and estimates peak sales potential of $1.5-2.0 billion.
Related stories
Neurocrine Biosciences Reports Strong Q3 Results, RBC Says
RBC described Neurocrine Biosciences' Q3 results as strong.
M impact | EQUITY | Nov 03, 2026, 04:39 PM UTC
US API Gasoline Stock Change
L impact | EQUITY | Nov 03, 2026, 04:38 PM UTC
US API Distillate Stock Change
L impact | EQUITY | Nov 03, 2026, 04:38 PM UTC
US API Cushing Stock Change
L impact | EQUITY | Nov 03, 2026, 04:38 PM UTC
Western Investment Company Raises $55.9M in Private Placement
Western issued 55,865,500 shares at $1.00 each, raising gross proceeds of $55.9 million. Net proceeds are expected to fund its previously announced Canadian Farm and Stockmens acqu
M impact | EQUITY | Nov 03, 2026, 04:37 PM UTC
Kolte-Patil Returns to Profit as Q2 Revenue More Than Doubles
Kolte-Patil Developers reported consolidated net profit of ₹5.3 crore for FY27’s second quarter, versus a net loss of ₹10.4 crore a year earlier. Revenue more than doubled year on
M impact | EQUITY | Nov 03, 2026, 04:36 PM UTC